Comparative Analysis of NAT, TRFIA, and ELISA for Screening Blood‐Borne Pathogens in Preoperative and Pre‐Transfusion Patients
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.71125 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Juan Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Blood-Borne Infections, Blood-Borne Pathogens, Nucleic Acid Amplification Techniques, Mass Screening. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Key Medical Research Project in Xi'an City, Matching Fund Project of The First Affiliated Hospital of Xi'an Medical University.
Abstract (Originalsprache)
This retrospective single‐center study compared nucleic acid testing (NAT), time‐resolved fluorescence immunoassay (TRFIA), and enzyme‐linked immunosorbent assay (ELISA) for screening hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and Treponema pallidum (TP) among 1243 preoperative and pre‐transfusion patients. Specimens were detected by pathogen‐targeted NAT, serological TRFIA and routine ELISA panels, respectively. HBV positive rates were 2.17% (NAT), 2.09% (TRFIA) and 1.53% (ELISA); HCV positive rates were 0.08%, 0.24% and 0.08%, without statistical intergroup differences (all p > 0.05). TRFIA yielded a significantly higher TP positive rate than ELISA (0.88% versus 0.40%, p < 0.05), while no HIV‐positive specimens were identified in this cohort. Kappa tests showed moderate‐to‐good consistency for HBV (0.711–0.842) and perfect concordance between NAT and ELISA for HCV (Kappa = 1.000). Twenty‐three discordant samples were found, including eight NAT‐only HBV positives suggestive of potential window‐period infections and six TRFIA‐only TP positives. Limited by an obstetric‐female‐dominated cohort, scarce HCV cases, and zero HIV positives, standard diagnostic accuracy metrics could not be comprehensively evaluated. NAT and TRFIA exhibit complementary screening values, yet their combined application may increase false‐positive risks and lacks systematic cost‐effectiveness evidence to support large‐scale clinical implementation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The First Affiliated Hospital of Xi'an Medical University, Xi'an, China.
Förderung
- Key Medical Research Project in Xi'an City
- Matching Fund Project of The First Affiliated Hospital of Xi'an Medical University
Zitieren
APA
Gao, J., Ma, M., Zhang, Y., Wang, X., Li, R., Xue, J., Ren, X., & Li, Z. (2026). Comparative Analysis of NAT, TRFIA, and ELISA for Screening Blood‐Borne Pathogens in Preoperative and Pre‐Transfusion Patients. Journal of Medical Virology. https://doi.org/10.1002/jmv.71125
Vancouver
Gao J, Ma M, Zhang Y, Wang X, Li R, Xue J, et al. Comparative Analysis of NAT, TRFIA, and ELISA for Screening Blood‐Borne Pathogens in Preoperative and Pre‐Transfusion Patients. Journal of Medical Virology. 2026. doi:10.1002/jmv.71125
BibTeX
@article{Gao2026,
author = {Gao, Juan and Ma, Mengying and Zhang, Yaya and Wang, Xin and Li, Rui and Xue, Juan and Ren, Xuemei and Li, Zhuo},
title = {Comparative Analysis of NAT, TRFIA, and ELISA for Screening Blood‐Borne Pathogens in Preoperative and Pre‐Transfusion Patients},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.71125}
}
EUVIMED